[18F]AlF-CBP靶向I型胶原PET显像用于临床前模型肺纤维化的无创监测
研究开发了靶向I型胶原的PET探针[18F]AlF-CBP,在体外验证其稳定性(>95%)和I型胶原特异性(IC50=0.36 µM)。纤维化小鼠模型肺内探针摄取和滞留高于对照组,放射性信号与纤维化程度正相关(CT:R2=0.89,P<0.0001;羟脯氨酸水平:R2=0.89,P<0.0001)。非人灵长类肺纤维化模型中PET信号与平均肺密度相关(R2=0.84,P<0.0001)。
要点
- [18F]AlF-CBP在体外和体内稳定性>95%,靶向I型胶原的IC50=0.36 µM。
- 纤维化小鼠模型肺探针摄取和滞留高于对照组,信号与CT纤维化程度及羟脯氨酸水平正相关(R2=0.89,P<0.0001)。
- 非人灵长类肺纤维化模型中PET信号与平均肺密度相关(R2=0.84,P<0.0001)。
核心结论
- [18F]AlF-CBP PET显像是一种有前景的无创方法,可特异性监测肺纤维化进展和疗效。
研究设计与样本
- 临床前研究:设计靶向I型胶原的18F标记PET探针[18F]AlF-CBP,体外评估结合亲和力、特异性和稳定性。
- 在纤维化小鼠模型中进行PET、CT、组织病理学、免疫荧光和生化指标检测以评估I型胶原水平和肺纤维化进展及治疗。
- 在非人灵长类肺纤维化模型中进行[18F]AlF-CBP动态PET/CT研究。
主要发现
- [18F]AlF-CBP成功制备,体外和体内试验显示高稳定性(>95%)和I型胶原特异性(IC50=0.36 µM)。
- 纤维化小鼠模型肺内探针摄取和滞留高于对照组,放射性摄取信号与纤维化程度正相关(CT:R2=0.89,P<0.0001;羟脯氨酸水平:R2=0.89,P<0.0001)。
- 非人灵长类肺纤维化模型中PET信号与平均肺密度相关(R2=0.84,P<0.0001)。
关键数值与推荐
- [18F]AlF-CBP的I型胶原靶向特异性以IC50=0.36 µM表示。
- 探针稳定性>95%。
- 小鼠模型放射性信号与CT纤维化程度相关R2=0.89(P<0.0001),与羟脯氨酸水平相关R2=0.89(P<0.0001)。
- 非人灵长类模型PET信号与平均肺密度相关R2=0.84(P<0.0001)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pulmonary fibrosis is an irreversible scar-forming condition for which there is a lack of non-invasive and specific methods for monitoring its progression and therapy efficacy. However, the disease is known to be accompanied by collagen accumulation. Here, we developed a novel positron emission tomography (PET) probe targeting type I collagen to evaluate its utility for the non-invasive assessment of pulmonary fibrosis. METHODS: We designed a 18F-labeled PET probe ([18F]AlF-CBP) to target type I collagen and evaluated its binding affinity, specificity and stability in vitro. PET with [18F]AlF-CBP, CT, histopathology, immunofluorescence, and biochemical indice were performed to assess and quantify type I collagen levels and pulmonary fibrosis progression and treatment in murine models. Dynamic PET/CT studies of [18F]AlF-CBP were conducted to assess lung fibrosis in non-human primate models. RESULTS: [18F]AlF-CBP was successfully prepared, and in vitro and in vivo tests showed high stability (> 95%) and type I collagen specificity (IC50 = 0.36 µM). The lungs of the fibrotic murine model showed more elevated probe uptake and retention compared to the control group, and there was a positive correlation between the radioactivity uptake signals and the degree of fibrosis (CT: R2 = 0.89, P < 0.0001; hydroxyproline levels: R2 = 0.89, P < 0.0001). PET signals also correlated well with mean lung density in non-human primate models of pulmonary fibrosis (R2 = 0.84, P < 0.0001). CONCLUSION: [18F]AlF-CBP PET imaging is a promising non-invasive method for specific monitoring of lung fibrosis progression and therapy efficacy.
引用
- Liu Y, Tang P, Peng S, et al. [18F]AlF-CBP imaging of type I collagen for non-invasive monitoring of pulmonary fibrosis in preclinical models. Eur J Nucl Med Mol Imaging. 2024. PMID: 39172179. doi:10.1007/s00259-024-06888-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。